替加环素对台湾地区气单胞菌、弧菌及沙门菌临床分离株的体外活性
In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
作者信息
Liu Chia-Ying, Huang Yu-Tsung, Liao Chun-Hsing, Hsueh Po-Ren
机构信息
Section of Infectious Diseases, Department of Internal Medicine, Far-Eastern Memorial Hospital, Taiwan.
出版信息
Antimicrob Agents Chemother. 2008 Jul;52(7):2677-9. doi: 10.1128/AAC.00002-08. Epub 2008 May 12.
Abstract
All 198 Salmonella isolates (58.6% of isolates were resistant to tetracycline), 92 Vibrio isolates (4.4% of isolates were resistant to tetracycline), and 200 of 201 Aeromonas isolates (39.3% of isolates were resistant to tetracycline; 1 A. caviae isolate had a tigecycline MIC of 4 mug/ml) in our study were susceptible to tigecycline, by U. S. Food and Drug Administration criteria for Enterobacteriaceae.
摘要
根据美国食品药品监督管理局针对肠杆菌科的标准，我们研究中的所有198株沙门氏菌分离株（58.6%的分离株对四环素耐药）、92株弧菌分离株（4.4%的分离株对四环素耐药）以及201株气单胞菌分离株中的200株（39.3%的分离株对四环素耐药；1株豚鼠气单胞菌分离株的替加环素最低抑菌浓度为4μg/ml）对替加环素敏感。
相似文献
1
In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.
Antimicrob Agents Chemother. 2008 Jul;52(7):2677-9. doi: 10.1128/AAC.00002-08. Epub 2008 May 12.
2
In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus.
J Microbiol Immunol Infect. 2018 Feb;51(1):76-81. doi: 10.1016/j.jmii.2016.04.009. Epub 2016 May 13.
3
Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.
J Med Microbiol. 2009 Mar;58(Pt 3):337-341. doi: 10.1099/jmm.0.47853-0.
4
In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.
Antimicrob Agents Chemother. 2011 Jun;55(6):2755-9. doi: 10.1128/AAC.01807-10. Epub 2011 Mar 14.
5
The tetA gene decreases tigecycline sensitivity of Salmonella enterica isolates.
Int J Antimicrob Agents. 2013 Aug;42(2):133-40. doi: 10.1016/j.ijantimicag.2013.04.017. Epub 2013 Jun 6.
6
Bacterial aetiology of diarrhoeal diseases and antimicrobial resistance in Dhaka, Bangladesh, 2005-2008.
Epidemiol Infect. 2012 Sep;140(9):1678-84. doi: 10.1017/S0950268811002135. Epub 2011 Nov 1.
7
Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
Diagn Microbiol Infect Dis. 2005 Jul;52(3):209-13. doi: 10.1016/j.diagmicrobio.2005.06.010.
8
Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Ann Clin Microbiol Antimicrob. 2017 Jul 12;16(1):50. doi: 10.1186/s12941-017-0222-0.
9
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.
10
Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M).
J Antimicrob Chemother. 2016 Apr;71(4):871-81. doi: 10.1093/jac/dkv420. Epub 2015 Dec 18.
引用本文的文献
1
The Impact of Cefuroxime Susceptibility on Necrotizing Fasciitis Outcomes.
Microorganisms. 2023 Nov 15;11(11):2776. doi: 10.3390/microorganisms11112776.
2
Antimicrobial resistance among clinical non-O1/non-O139 isolates: systematic review and meta-analysis.
Pathog Glob Health. 2023 May;117(3):235-244. doi: 10.1080/20477724.2022.2114620. Epub 2022 Aug 19.
3
Epidemiology, Serogroups and Resistance of During a 15-Year Period (2006-2020) in Kuwait.
Infect Drug Resist. 2021 Nov 25;14:4957-4966. doi: 10.2147/IDR.S340116. eCollection 2021.
4
Synergy and Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00310-19. Print 2019 Oct.
5
Multidrug-resistant (MDR) Aeromonas recovered from the metropolitan area of Valencia (Spain): diseases spectrum and prevalence in the environment.
Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):137-145. doi: 10.1007/s10096-014-2210-z. Epub 2014 Aug 2.
6
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Antimicrob Agents Chemother. 2012 Jun;56(6):2916-22. doi: 10.1128/AAC.00110-12. Epub 2012 Apr 2.
7
Which antibiotics and breakpoints should be used for Aeromonas susceptibility testing? Considerations from a comparison of agar dilution and disk diffusion methods using Enterobacteriaceae breakpoints.
Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2369-77. doi: 10.1007/s10096-012-1578-x. Epub 2012 Feb 27.
8
In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.
Antimicrob Agents Chemother. 2011 Jun;55(6):2755-9. doi: 10.1128/AAC.01807-10. Epub 2011 Mar 14.
9
In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.
Eur J Clin Microbiol Infect Dis. 2009 Dec;28(12):1437-42. doi: 10.1007/s10096-009-0801-x. Epub 2009 Sep 8.
本文引用的文献
1
EUCAST technical note on tigecycline.
Clin Microbiol Infect. 2006 Nov;12(11):1147-9. doi: 10.1111/j.1469-0691.2006.01578.x.
2
Prognostic factors and antibiotics in Vibrio vulnificus septicemia.
Arch Intern Med. 2006 Oct 23;166(19):2117-23. doi: 10.1001/archinte.166.19.2117.
3
Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
Antimicrob Agents Chemother. 2006 Aug;50(8):2695-9. doi: 10.1128/AAC.00155-06.
4
Tigecycline: a critical analysis.
Clin Infect Dis. 2006 Aug 15;43(4):518-24. doi: 10.1086/505494. Epub 2006 Jun 26.
5
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.
Antimicrob Agents Chemother. 2005 Nov;49(11):4658-66. doi: 10.1128/AAC.49.11.4658-4666.2005.
6
Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
Diagn Microbiol Infect Dis. 2005 Jul;52(3):209-13. doi: 10.1016/j.diagmicrobio.2005.06.010.
7
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Int J Infect Dis. 2005 Sep;9(5):251-61. doi: 10.1016/j.ijid.2005.05.003.
8
Bacterial food-borne illness outbreaks in northern Taiwan, 1995-2001.
J Infect Chemother. 2005 Jun;11(3):146-51. doi: 10.1007/s10156-005-0383-1.
9
Increasing ceftriaxone resistance in Salmonella isolates from a university hospital in Taiwan.
J Antimicrob Chemother. 2005 Jun;55(6):846-52. doi: 10.1093/jac/dki116. Epub 2005 May 4.
10
Vibrio vulnificus in Taiwan.
Emerg Infect Dis. 2004 Aug;10(8):1363-8. doi: 10.3201/eid1008.040047.
Zotero 插件